Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaime Vera

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
The Lancet. HIV|February 28, 2024
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trialGraeme Moyle, Lambert Assoumou, Nathalie de Castro, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|March 23, 2026
Current Perspectives and Emerging Directions in Research and Practice: Highlights from the 15th Annual International Workshop on Aging and HIVJun Y Byun, Raymond Jones, Evelyn Iriarte, et al.
BMC Infectious Diseases|February 28, 2024
Independent clinic-based evaluation of dual POCTs for screening for HIV and syphilis in men who have sex with men in Italy, Malta, Peru, and the United KingdomNigel Sherriff, Massimo Mirandola, Ronaldo Silva, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 19, 2018
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 StudyJosé M Gatell, Lambert Assoumou, Graeme Moyle, et al.
The Lancet. HIV|November 30, 2024
Fostering healthy cognitive ageing in people living with HIVLucette A Cysique, Jules Levin, Chris Howard, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
The Lancet. HIV|February 28, 2024
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trialGraeme Moyle, Lambert Assoumou, Nathalie de Castro, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|March 23, 2026
Current Perspectives and Emerging Directions in Research and Practice: Highlights from the 15th Annual International Workshop on Aging and HIVJun Y Byun, Raymond Jones, Evelyn Iriarte, et al.
BMC Infectious Diseases|February 28, 2024
Independent clinic-based evaluation of dual POCTs for screening for HIV and syphilis in men who have sex with men in Italy, Malta, Peru, and the United KingdomNigel Sherriff, Massimo Mirandola, Ronaldo Silva, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 19, 2018
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 StudyJosé M Gatell, Lambert Assoumou, Graeme Moyle, et al.
The Lancet. HIV|November 30, 2024
Fostering healthy cognitive ageing in people living with HIVLucette A Cysique, Jules Levin, Chris Howard, et al.
Pageof 4